pharma · Metastatic Melanoma · Unresectable Melanoma · IOVA
Iovance Biotherapeutics
Iovance Biotherapeutics B.V.
Iovance Biotherapeutics is a pharma organization headquartered in San Carlos, USA. It trades on NYSE under ticker IOVA. Primary therapeutic focus areas include Metastatic Melanoma, Unresectable Melanoma, Metastatic Non-S
825 Industrial Rd, Suite 400, San Carlos, California 94070, US HQ
2007 Founded
916 Employees
Public company Type
IOVA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 825 Industrial Rd, Suite 400, San Carlos, California 94070, US
- Founded
- 2007
- Employees
- 916
- Programs
- 36
- Drugs
- 26
- Patents
- 94
Lifileucel plus Pembrolizumab
Phase 3 · mab · Metastatic Melanoma
Lifileucel plus Pembrolizumab for Metastatic Melanoma is a Phase 3 program (mab) at Iovance Biotherapeutics B.V. with 1 ClinicalTrials.gov record(s).
Internal code IOV-MEL-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Iovance Biotherapeutics B.V.
- Phase
- Phase 3
- Modality
- mab
- Indication
- Metastatic Melanoma
- Status
- active
- Trials
- 1